CMS Negotiates Discounts on 15 Drugs, Including Cancer Therapies
CMS has secured significant price reductions on 15 drugs including costly cancer treatments, impacting Medicare Part B pricing and healthcare costs.
Medicare Diabetes Prevention Program Faces Low Enrollment and Operational Challenges
The Medicare Diabetes Prevention Program has enrolled less than 1% of eligible beneficiaries since 2018 due to administrative, referral, and awareness challenges despite proven effectiveness. CMS changes aim to improve access and provider reimbursement.
CMS Expands Medicare Drug Price Negotiations to 25 Medications
CMS expands Medicare drug price controls to 25 medications, achieving $12 billion savings with new Maximum Fair Prices starting 2026 and 2027 for chronic and cancer treatments.
CMS Proposes 2027 Updates to Medicare Advantage and Part D Star Ratings
CMS has proposed key 2027 updates to Medicare Advantage and Part D Star Ratings aiming to streamline quality measures and modernize enrollment options to enhance care and plan accountability.
HHS-OIG Flags $39.6M in Podiatry E/M Billing for CMS Oversight
HHS-OIG audit uncovers $39.6 million in potentially improper podiatry E/M payments, urging CMS to enhance Medicare oversight in billing practices.
CMS Launches 2026 Drug Acquisition Cost Survey for Medicare OPPS Hospitals
CMS will conduct a drug acquisition cost survey in early 2026 to collect data from hospitals under the Medicare OPPS, informing 2027 outpatient payment policies.
CMS Launches ACCESS Model to Advance Medicare Chronic Care with Digital Tools
CMS introduces the ACCESS Model to enhance chronic care for Medicare beneficiaries using digital health tools and outcome-based payment models starting in 2026.
GAO Identifies Fraud Gaps in ACA Marketplaces Allowing Fake Enrollment
GAO report reveals fraud vulnerabilities in ACA marketplaces with fake enrollments approved in 2024-25, urging stronger fraud controls and verification in federal marketplaces.
CMS Announces 2027 Medicare Part D Drug Price Reductions for 15 High-Cost Medications
CMS reveals new 2027 price caps for 15 Medicare Part D drugs, projected to save billions federally and reduce patient costs under the Inflation Reduction Act negotiations.
CMS Launches ACCESS Model to Advance Technology-Enabled Chronic Care in Medicare
CMS introduces the ACCESS Model, a voluntary Medicare initiative that promotes technology-enabled chronic care solutions to improve patient outcomes and modernize Medicare treatment frameworks.